The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...

This medication is injected into a vein as directed by your doctor. The dosage and length of treatment are based on your medical condition and response to treatment. Children's dosage may also be ...

Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a ...

Inserting, monitoring, and maintaining peripheral venous access is an integral component of neonatal nursing care. Although complications associated with peripheral vascular devices are typically ...

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

Objective: To characterize the pharmacokinetic-pharmacodynamic correlation of intranasal and intravenous fentanyl in opioid-naïve patients undergoing third molar extraction. Methods: A double ...

Approval was based on results from multiple studies, which demonstrated a slowing of cognitive decline in patients with ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

"We have been slow in finding solutions for preventing infections from intravenous catheters," said Althumayri. "A reason could be that we lack good platforms to test new catheter designs or ...

With the world running low on saline IV, a NSW vet discovers how to keep the precious resource flowing to animal clinics and ...